Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Accumulated Expenses of $11.3 million for Q1 2026, down 6.51% year-over-year from $12.1 million in Q1 2025, and down 37.01% quarter-over-quarter from $17.9 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $11.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 6.51% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.3 million (down 6.51% YoY), while the FY2025 annual figure was $17.9 million, down 25.22% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $11.3 million, down from $17.9 million in the prior quarter.
- The five-year high for Accumulated Expenses was $67.9 million in Q1 2024, with the low at $3.6 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $23.9 million (2024), against an average of $30.1 million.
- The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 982.18% in 2023, then plunged 82.22% in 2025.
- Amylyx Pharmaceuticals' Accumulated Expenses stood at $38.3 million in 2022, then soared by 50.67% to $57.7 million in 2023, then slumped by 58.51% to $23.9 million in 2024, then declined by 25.22% to $17.9 million in 2025, then sank by 37.01% to $11.3 million in 2026.
- Business Quant data shows AMLX's Accumulated Expenses at $11.3 million in Q1 2026, $17.9 million in Q4 2025, and $19.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.61 Mn |
| Mar 31, 2026 | 11.28 Mn |
| Dec 31, 2025 | 17.91 Mn |
| Sep 30, 2025 | 19.47 Mn |
| Jun 30, 2025 | 17.47 Mn |
| Mar 31, 2025 | 12.07 Mn |
| Dec 31, 2024 | 23.95 Mn |
| Sep 30, 2024 | 50.46 Mn |
| Jun 30, 2024 | 62.76 Mn |
| Mar 31, 2024 | 67.87 Mn |
| Dec 31, 2023 | 57.72 Mn |
| Sep 30, 2023 | 37.05 Mn |
| Jun 30, 2023 | 37.24 Mn |
| Mar 31, 2023 | 38.75 Mn |
| Dec 31, 2022 | 38.31 Mn |
| Sep 30, 2022 | 8.99 Mn |
| Jun 30, 2022 | 6.48 Mn |
| Mar 31, 2022 | 3.58 Mn |
| Dec 31, 2021 | 4.28 Mn |